---
layout: post
title: "Graph Neural Networks in Drug Discovery"
subtitle: "Leveraging Graph-Based Deep Learning for Pharmaceutical Innovation (thumbnail by IconScout)"
# cover-img: /assets/img/gnn_drug_discovery.png
thumbnail-img: /assets/img/gnn_drug_discovery_thumb.png
tags: [graph neural networks, drug discovery, deep learning, bioinformatics]
author: Ali Reza Sabounchi
---

It seems as though the topic of GNNs in drug discovey is as relevant as it was back in 2021 when I first became familiar with the topic myself, although is as been overshadowed by more recent, flashier cousins like LLMs and Diffusion models. Alas, the power of graphs in modeling chemical structures cannot be underestimaetd.

The integration of graph neural networks (GNNs) into drug discovery processes has surely opened new avenues for understanding complex biochemical interactions. By modeling molecular structures as graphs, GNNs can provide a framework to predict molecular properties, interactions, and potential therapeutic effects, all with respect to the chemical structure of the molecule, which may not be sufficiently utilized in other methods.

### Understanding Graph Neural Networks (at least how I understand them!)

GNNs are a class of deep learning models designed to operate on graph-structured data (like molecules). In the context of chemistry, molecules are naturally represented as graphs, with atoms as nodes and chemical bonds as edges. This representation allows GNNs to learn from the connectivity and features of atoms and bonds, which helps capture the intricacies of molecular structures. Even using numerous chemical descriptors, it may still not be possible to express the differences between structures that are fundamentally unlike one another when it comes to their 3D conformation as well as a GNN can.

### Applications in Drug Discovery (as far as I know!)

GNNs can predict properties such as bioactivity, toxicity, and solubility by learning from large datasets of molecular graphs. In my own RA experience, I worked extensively on the MoleculeNet dataset, which included all the aforementioned tasks. GNNs can also model interactions between proteins, aiding in understanding disease mechanisms and identifying potential drug targets, although this use case might not be as straightforward as the property prediction, since modeling proteins is a bit more complicated due to them having a hierarchical structure level system. Lastly, when it comes to analyzing the compatibility between drug molecules and target proteins, GNNs can also assist in identifying promising drug candidates.

One my first introductions into the topic of GNN applications in drug discovery was AtomNet, a deep learning system that predicts bioactivity of small molecules for drug design. AtomNet, allegedly(!), was used to predict novel candidate biomolecules for disease targets such as the Ebola virus. This means that the usefulness of this approach is not mere hype, but has actual data to back it up (a.k.a it is not AI slop).

### (Dis)Advantages of GNNs

- **Structural Awareness**: GNNs inherently consider the spatial arrangement of molecules, leading to more accurate predictions (when 3D structure matters).

- **Data Efficiency**: They can learn effectively from limited data by leveraging the relational information in molecular graphs (although they are infamously more prone to over-smoothing if the architecture is too deep / data is limited).

While GNNs offer significant advantages, challenges such as interpretability (or more precisely, chemically / clinically meaningful information from post-hoc explanation methods), computational complexity, and the need for large, high-quality datasets remain.

### Conclusion

I like GNNs. They represent a transformative approach in drug discovery, which allow for more precise modeling of molecular interactions and properties. However, they are a long way from being trustworthy enough (largely due to poor interpretability) to replace methods based on chemical descriptors or fingerprints.

